Engitix, a biotechnology company with a portfolio of programmes in fibrosis and solid tumours and two significant partnerships based on its proprietary human extracellular matrix (ECM) platform, has announced that it is relocating its headquarters and operations to WestWorks, part of Stanhope’s White City Place.
The move follows announcements of high-profile collaboration agreements with Takeda Pharmaceuticals and Morphic Therapeutic, to leverage the benefits of Engitix’ human ECM-based discovery platform to improve the success rate of drug discovery and development.
The collaborations with major pharma industry players have prompted the expansion, which starts with it moving to the 8,000 square feet facility of bespoke office and laboratory space in WCP.
Engitix joins GammaDelta Therapeutics, Autolus and Synthace, as well as Novartis, in the emerging White City bioscience cluster.
Stephen Brindle, COO of Engitix said:“Our move and expansion into this new, inspiring hub in White City is a significant milestone for Engitix. Here, we will have the ideal premises to accommodate further growth as we look to double in size in the coming years, driven by progess with both our proprietary programmes and major partnerships. As it emerges as a new centre in the field of life sciences, White City also gives us access to excellent facilities and networking opportunities for industry players.”
David Camp, CEO, Stanhope PLC, the developer and owner of WCP, stated: “We are delighted that Engitix have decided to relocate their head office to the growing life sciences cluster at the WestWorks building in White City Place. The addition of Engitix Therapeutics helps further enhance White City Place’s status as the number one location of choice for innovative, forward thinking companies in the life sciences and biotech sector.”
